Interview with Zheng-Rong Lu
I was attracted to the field of nucleic acid therapeutics by the news of 2006 Nobel Prize in Medicine to Andrew Fire and Craig Mello when I was a junior
Details……………
Interview with Jeroen Bremer
I became interested into the field of RNA-therapeutics during an internship at the department of Dermatology at the UMCG. Together with Peter van den
Details
Interview with Annika de Jong
The first internship of my master was performed at the department of Human Genetics at the Leiden University Medical Centre where Prof. AnnemiekeAartsma-Rus
Details
Interview with Robert Habib
In 2013 I was seeking to run a business that could have an impact in healthcare. John Rossi, Pål Sætrom and Nagy Habib had put together the initial features
Details
Interview with Vadim Y Dudkin
I first became exposed to oligonucleotide delivery while at Merck upon the acquisition of Sirna in 2006. Part of my work at the time involved glyco
Details
Interview with Hannah Pendergraff
I became interested in oligo therapeutics when I started working in David Corey’s lab. I joined his group in 2009…
Details
Interview with Keith T. Gagnon
I was thrown into the world of nucleic acid therapeutics during my postdoc with David Corey. My Ph.D. training focused on the…
Details
Interview with Paul Burke
Paul Burke, PhD Principal, Burke Bioventures LLC How did you become interested in the field of oligonucleotides? I first became interested in
Details
Interview with Kotaro Yoshioka
Kotaro Yoshioka, MD, PhD Department of Neurology and Neurological Science, Tokyo Medical and Dental University How did you become interested in the field of
Details
Interview with Thorleif Møller
ThorleifMøller, PhD Mirrx Therapeutics A/S CEO & Founder How did you become interested in the field of oligonucleotides? During my PhD studies at the
Details
Interview with Sebastien Burel
Sebastien Burel, PhD Ionis Pharmaceuticals Director Nonclinical Development How did you become interested in the field of oligonucleotides? Mostly by accident.
Details
Interview with Professor J George Dickson
Professor J George Dickson Chair of Molecular Cell Biology, School of Biological Sciences Royal Holloway – University of London, Egham, Surrey, TW20 0EX, UK.
Details
Interview with Catherine McKeen, PhD
Catherine McKeen, PhD Operations Director Link Technologies How did you become interested in the field of oligonucleotides? I have worked in the oligonucleotide sector since 1994. Initially I worked with Tom Brown in
Details
Interview with Jean Gariepy
Jean Gariepy, Ph.D. Professor Departments of Medical Biophysics and Pharmaceutical Sciences University of Toronto SRI Research Chair in Biomolecular Engineering and Senior Scientist Physical Sciences Sunnybrook Research Institute
Details
Interview with Simon C. W. Richardson
SIMON C. W. RICHARDSON BSc (Hons) MSc PhD FRSB CBiol. Director at Intracellular Delivery Solutions Ltd., and Senior Lecturer in Biopharmaceutics, University of Greenwich, UK. How did you become interested in the field of
Details
Interview with Maire Fiona Osborn, Ph.D.
Maire Fiona Osborn, Ph.D. Postdoctoral Associate, RNA Therapeutics Institute University of Massachusetts Medical School How did you become interested in the field of oligonucleotides? I took a somewhat circuitous route to the field of
Details
Interview with Xianbin Yang, PhD, MBA
Xianbin Yang, PhD, MBA Director AM Biotechnologies How did you become interested in the field of oligonucleotides? I’ve been fascinated with nucleic acid chemistry and biology since my undergraduate study. I received my
Details
Interview with Eli Gilboa, PhD
Eli Gilboa Ph.D. Dodson Professor of Microbiology & Immunology University of Miami Miller School of Medicine How did you become interested in the field of oligonucleotides? A main interest and focus of my lab is cancer immunotherapy. The overall approach has been
Details
Interview with Maureen McKeague, PhD
Maureen McKeague, PhD, Postdoctoral Scholar, Bioengineering Department, Stanford University How did you become interested in the field? I’ve been fascinated with nucleic acids ever since high school biology. In my undergraduate degree, I enjoyed genetics
Details
Interview with Bart Klein
ProQR Therapeutics Property, Head of Intellectual Property How did you become interested in the field? I am a Dutch and European patent attorney with a Masters in Chemical Biology/Molecular Biology from Utrecht University, The Netherlands (Msc. 1988).
Details
Interview with Gerald Zon, PhD, FRSC
How did you become interested in the field? I was working in 1981 as an organic chemist at NIH in the former FDA Bureau of Biologics (now Center for Drug Evaluation & Research), and was asked to help clone the gene for human C-reactive protein by making the required hybridization probe—a mixed-sequence 11-mer oligodeoxynucleotide,
Details
Interview with Takenori Shimo, Doctoral Candidate at Osaka University
Takenori Shimo received both his B.S. and M.Sc. in Pharmaceutical Sciences from Osaka University, Japan. He is currently a doctoral candidate in the Graduate School of Pharmaceutical Sciences, Osaka University. His research interests include nucleic acid chemistry, especially modulating splicing by using antisense oligonucleotides.
Details
Interview with Paloma H. Giangrande, PhD
Paloma H. Giangrande, PhD Associate Professor, Department of Internal Medicine, University of Iowa Scientific Advisory Council Member, Oligonucleotide Therapeutics Society Giangrande_Photo Dr. Paloma H. Giangrande Paloma H. Giangrande, PhD, is an Associate Professor in the Department of Internal Medicine at The University
Details
Interview with Fritz Eckstein, PhD – OTS Honorary Board Member
Science: Q: Paul Zamecnik and Mary Stephenson in 1978 reported the very first studies on antisense mechanisms of gene silencing. Since the inception of this field – how far have we come – both in basic and therapeutic research & development? A: The original antisense mechanism has been joined
Details